Endothelin type A receptor antagonist normalizes blood pressure in rats exposed to eucapnic intermittent hypoxia

Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H434-40. doi: 10.1152/ajpheart.91477.2007. Epub 2008 May 30.

Abstract

We have reported that eucapnic intermittent hypoxia (E-IH) causes systemic hypertension, elevates plasma endothelin 1 (ET-1) levels, and augments vascular reactivity to ET-1 and that a nonspecific ET-1 receptor antagonist acutely lowers blood pressure in E-IH-exposed rats. However, the effect of chronic ET-1 receptor inhibition has not been evaluated, and the ET receptor subtype mediating the vascular effects has not been established. We hypothesized that E-IH causes systemic hypertension through the increased ET-1 activation of vascular ET type A (ET(A)) receptors. We found that mean arterial pressure (MAP) increased after 14 days of 7 h/day E-IH exposure (109 +/- 2 to 137 +/- 4 mmHg; P < 0.005) but did not change in sham-exposed rats. The ET(A) receptor antagonist BQ-123 (10 to 1,000 nmol/kg iv) acutely decreased MAP dose dependently in conscious E-IH but not sham rats, and continuous infusion of BQ-123 (100 nmol.kg(-1).day(-1) sc for 14 days) prevented E-IH-induced increases in MAP. ET-1-induced constriction was augmented in small mesenteric arteries from rats exposed 14 days to E-IH compared with those from sham rats. Constriction was blocked by the ET(A) receptor antagonist BQ-123 (10 microM) but not by the ET type B (ET(B)) receptor antagonist BQ-788 (100 microM). ET(A) receptor mRNA content was greater in renal medulla and coronary arteries from E-IH rats. ET(B) receptor mRNA was not different in any tissues examined, whereas ET-1 mRNA was increased in the heart and in the renal medulla. Thus augmented ET-1-dependent vasoconstriction via vascular ET(A) receptors appears to elevate blood pressure in E-IH-exposed rats.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / pharmacology*
  • Blood Pressure / drug effects*
  • Coronary Vessels / drug effects
  • Coronary Vessels / physiopathology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endothelin A Receptor Antagonists*
  • Endothelin B Receptor Antagonists
  • Endothelin-1 / metabolism*
  • Hypertension / etiology
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Hypertension / prevention & control*
  • Hypoxia / complications
  • Hypoxia / drug therapy*
  • Hypoxia / metabolism
  • Hypoxia / physiopathology
  • Infusions, Parenteral
  • Male
  • Mesenteric Arteries / drug effects
  • Mesenteric Arteries / physiopathology
  • Oligopeptides / pharmacology
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / pharmacology*
  • Piperidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Endothelin A / genetics
  • Receptor, Endothelin A / metabolism
  • Renal Artery / drug effects
  • Renal Artery / physiopathology
  • Time Factors
  • Vasoconstriction / drug effects

Substances

  • Antihypertensive Agents
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Endothelin-1
  • Oligopeptides
  • Peptides, Cyclic
  • Piperidines
  • Receptor, Endothelin A
  • BQ 788
  • cyclo(Trp-Asp-Pro-Val-Leu)